IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

Patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer show a dramatic response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired drug resistance eventually develops. This study explored the novel mechanisms related to TKI resistance. To identify the genes ass...

Full description

Bibliographic Details
Main Authors: Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Chia-Lang Hsu, Yih-Leong Chang, Chong-Jen Yu, Jin-Yuan Shih
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Cancers
Subjects:
EGFR mutation
insulin-like growth factor binding protein 7
epidermal growth factor receptor-tyrosine kinase inhibitor
acquired resistance
lung cancer
Online Access:http://www.mdpi.com/2072-6694/11/1/36

Internet

http://www.mdpi.com/2072-6694/11/1/36

Similar Items